|
Gene: SFT2D2 |
Gene summary for SFT2D2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SFT2D2 | Gene ID | 375035 |
Gene name | SFT2 domain containing 2 | |
Gene Alias | UNQ512 | |
Cytomap | 1q24.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O95562 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
375035 | SFT2D2 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.37e-08 | 3.45e-01 | -0.1954 |
375035 | SFT2D2 | A015-C-203 | Human | Colorectum | FAP | 2.31e-04 | -8.77e-02 | -0.1294 |
375035 | SFT2D2 | A001-C-108 | Human | Colorectum | FAP | 5.54e-06 | -1.71e-01 | -0.0272 |
375035 | SFT2D2 | A015-C-104 | Human | Colorectum | FAP | 2.71e-09 | -1.95e-01 | -0.1899 |
375035 | SFT2D2 | A001-C-014 | Human | Colorectum | FAP | 6.42e-03 | -4.43e-02 | 0.0135 |
375035 | SFT2D2 | A002-C-016 | Human | Colorectum | FAP | 6.95e-03 | -1.05e-01 | 0.0521 |
375035 | SFT2D2 | A001-C-203 | Human | Colorectum | FAP | 2.63e-02 | -7.89e-02 | -0.0481 |
375035 | SFT2D2 | A002-C-116 | Human | Colorectum | FAP | 1.57e-07 | -1.10e-01 | -0.0452 |
375035 | SFT2D2 | F034 | Human | Colorectum | FAP | 1.02e-03 | -8.77e-02 | -0.0665 |
375035 | SFT2D2 | LZE2T | Human | Esophagus | ESCC | 5.50e-06 | 9.45e-01 | 0.082 |
375035 | SFT2D2 | LZE4T | Human | Esophagus | ESCC | 1.19e-11 | 2.41e-01 | 0.0811 |
375035 | SFT2D2 | LZE7T | Human | Esophagus | ESCC | 2.21e-07 | 5.11e-01 | 0.0667 |
375035 | SFT2D2 | LZE20T | Human | Esophagus | ESCC | 3.52e-07 | 1.18e-01 | 0.0662 |
375035 | SFT2D2 | LZE22T | Human | Esophagus | ESCC | 6.52e-04 | 3.19e-01 | 0.068 |
375035 | SFT2D2 | LZE24T | Human | Esophagus | ESCC | 1.62e-15 | 2.57e-01 | 0.0596 |
375035 | SFT2D2 | LZE6T | Human | Esophagus | ESCC | 2.67e-03 | 1.74e-01 | 0.0845 |
375035 | SFT2D2 | P1T-E | Human | Esophagus | ESCC | 2.43e-09 | 4.49e-01 | 0.0875 |
375035 | SFT2D2 | P2T-E | Human | Esophagus | ESCC | 5.36e-59 | 1.06e+00 | 0.1177 |
375035 | SFT2D2 | P4T-E | Human | Esophagus | ESCC | 4.35e-30 | 6.81e-01 | 0.1323 |
375035 | SFT2D2 | P5T-E | Human | Esophagus | ESCC | 1.52e-23 | 3.48e-01 | 0.1327 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SFT2D2 | SNV | Missense_Mutation | novel | c.354G>T | p.Trp118Cys | p.W118C | O95562 | protein_coding | deleterious(0.01) | benign(0.075) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
SFT2D2 | SNV | Missense_Mutation | c.284A>G | p.Glu95Gly | p.E95G | O95562 | protein_coding | deleterious(0.01) | possibly_damaging(0.506) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SFT2D2 | SNV | Missense_Mutation | novel | c.74N>G | p.Ala25Gly | p.A25G | O95562 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-AA-A02W-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SFT2D2 | insertion | Frame_Shift_Ins | novel | c.284_285insAAAGCTCTCATTCT | p.Pro96LysfsTer9 | p.P96Kfs*9 | O95562 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SFT2D2 | SNV | Missense_Mutation | rs752233992 | c.196N>A | p.Ala66Thr | p.A66T | O95562 | protein_coding | tolerated(0.09) | benign(0.178) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SFT2D2 | SNV | Missense_Mutation | novel | c.223G>A | p.Ala75Thr | p.A75T | O95562 | protein_coding | tolerated(0.32) | benign(0.005) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
SFT2D2 | SNV | Missense_Mutation | novel | c.285G>T | p.Glu95Asp | p.E95D | O95562 | protein_coding | tolerated(0.23) | benign(0.013) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
SFT2D2 | SNV | Missense_Mutation | novel | c.313G>A | p.Val105Met | p.V105M | O95562 | protein_coding | tolerated(1) | benign(0.017) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SFT2D2 | SNV | Missense_Mutation | novel | c.200N>C | p.Val67Ala | p.V67A | O95562 | protein_coding | deleterious(0.05) | benign(0.042) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SFT2D2 | SNV | Missense_Mutation | c.11N>A | p.Leu4Gln | p.L4Q | O95562 | protein_coding | deleterious(0) | possibly_damaging(0.69) | TCGA-BG-A3PP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |